In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 401 to 412 of 412

TitleTypeExpected publication date
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over ID6407Technology appraisal guidanceTBC
VTS-270 for treating Niemann-Pick type C1 [ID1267]Highly specialised technologyTBC
Vutrisiran for treating transthyretin-related amyloidosis with cardiomyopathy ID6470Technology appraisal guidanceTBC
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]Technology appraisal guidance
Women's and reproductive health guidelinesNICE guidelineTBC
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]Technology appraisal guidanceTBC
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]Technology appraisal guidance
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]Technology appraisal guidanceTBC
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]Technology appraisal guidanceTBC
Zio XT for detecting cardiac arrhythmiasMedical technologies guidanceTBC
Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123]Technology appraisal guidanceTBC
Zuranolone for treating severe postnatal depression ID6431Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All